Rapid Novor
Kitchener
About Rapid Novor
Rapid Novor helps biotech and pharmaceutical companies extract the full potential of antibodies in ways never before possible. Thanks to our mass spectrometry and AI based protein sequencing, antibody discovery and antibody characterization services, researchers have furthered thousands of projects. We provide services and develop new technology that enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Our technology has the potential to unlock a new universe of discoveries that will shape future research, and benefit global health. At Rapid Novor, we believe that the journey to a world of more effective treatments that cost less and are easier to develop starts with decoding immunity. Biotech CRO Services, Antibody Discovery Platforms, Antibody Characterization Services, Mass Spectrometry Services, Next Generation Protein Sequencing technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $5.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2020)
- Website: rapidnovor.com
- Phone: +1 855 899 9990
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/rapid-novor-64988 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.